Business ❯ Pharmaceutical Industry

Clinical Research

Drug Development Collaboration Drug Approval Process Funding Innovation Regulatory Affairs Innovative Treatments AstraZeneca Trial Results Novo Nordisk Market Impact Partnerships Collaboration Agreements Drug Approval

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

UBT251 targets GLP‑1, GIP plus glucagon for a mechanistically distinct approach to weight management.

Monte Rosa’s MRT-8102 Shows Strong Phase 1 Biomarker Effects, Lifting Shares to 52-Week High

Nektar’s Alopecia Drug Misses Phase 2b Goal as Company Cites Ineligible Patients, Plans Phase 3

Bristol Myers Delays ADEPT-2 Alzheimer’s Psychosis Readout to 2026 After Site Irregularities

Belite Bio’s Tinlarebant Cuts Stargardt Lesion Growth 36% in Phase 3 Trial

AstraZeneca’s Baxdrostat Lowers 24-Hour Systolic BP by 14 mmHg in Phase 3, AHA Presentation Confirms

Lilly’s Oral GLP-1 Orforglipron Beats Farxiga and Placebo in Two Phase 3 Diabetes Trials

Harvard Team Releases PDGrapher, an AI to Predict Gene and Drug Combos That Reverse Diseased Cell States

Jaypirca Delivers Significant PFS Benefit Over Chemoimmunotherapy in First-Line CLL/SLL

Arvinas’ Vepdegestrant Delays Breast Cancer Progression Longer Than Faslodex